11/20
08:47 am
iccm
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 [Yahoo! Finance]
Low
Report
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 [Yahoo! Finance]
11/20
08:30 am
iccm
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
Low
Report
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
11/19
08:41 am
iccm
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health [Yahoo! Finance]
Low
Report
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health [Yahoo! Finance]
11/19
08:30 am
iccm
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
Medium
Report
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
11/8
10:53 am
iccm
IceCure gets favorable FDA AdCom vote for ProSense System [Seeking Alpha]
Medium
Report
IceCure gets favorable FDA AdCom vote for ProSense System [Seeking Alpha]
11/8
07:00 am
iccm
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
High
Report
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
11/5
05:37 am
iccm
IceCure Medical Ltd (NASDAQ: ICCM) was upgraded by analysts at Alliance Global Partners to a "strong-buy" rating.
Medium
Report
IceCure Medical Ltd (NASDAQ: ICCM) was upgraded by analysts at Alliance Global Partners to a "strong-buy" rating.
10/29
08:30 am
iccm
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
High
Report
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
10/21
08:30 am
iccm
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
Medium
Report
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
10/15
05:36 pm
iccm
IceCure Medical files to sell ordinary shares and warrants [Seeking Alpha]
Medium
Report
IceCure Medical files to sell ordinary shares and warrants [Seeking Alpha]
10/7
08:15 am
iccm
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
Low
Report
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
9/24
08:15 am
iccm
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
Medium
Report
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
9/16
08:00 am
iccm
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
Medium
Report
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
9/12
02:15 pm
iccm
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
Medium
Report
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
9/12
08:00 am
iccm
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
Low
Report
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
9/4
08:30 am
iccm
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
Medium
Report
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
8/28
08:30 am
iccm
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies
High
Report
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies